Ligand Pharmaceuticals (LGND) Earnings Date & Reports

Key Takeaways

• Adjusted diluted earnings per share (EPS) of $2.67 beat the consensus estimate of roughly $2.30, while total revenue of $78.75 million also came in above expectations.
• Royalty revenue climbed 51% year over year to $70.3 million, driven by the completed XOMA Royalty acquisition and continued momentum from key assets such as Filspari.
• The company posted a generally accepted accounting principles (GAAP) net loss of $1.43 per share, reflecting one-time XOMA transaction costs and non-cash mark-to-market adjustments on equity investments.
• Management raised full-year 2026 adjusted diluted EPS guidance to a range of $9.50 to $9.75, up from $9.00 to $9.50, while reaffirming its revenue outlook.
• Filspari became Ligand's largest royalty asset at an estimated $16.8 million for the quarter, up 85% year over year.
• Ligand ended the quarter with roughly $750 million in deployable capital to pursue additional royalty acquisitions and strategic investments.
• For additional context on this ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore the dedicated pages linked here.
• To discover AI-driven trading ideas across the broader market, explore Trending AI Robots.

Earnings Context and Why It Matters

Ligand Pharmaceuticals operates as a biopharmaceutical royalty aggregator, earning income by acquiring royalty rights to medicines developed by other companies rather than commercializing drugs itself. This quarter carries added significance because it is the first full reporting period to reflect the July 14, 2026 acquisition of XOMA Royalty, a transformative $739 million deal that more than doubled the company's portfolio to over 200 royalty assets. Investors are watching whether the enlarged royalty base can sustain growth, whether integration costs are manageable, and how management's capital deployment strategy translates into adjusted earnings. The report also offers an early read on Filspari's commercial trajectory following its April 2026 approval for a second rare kidney disease.

Reported Results

Ligand reported total revenue and income of $78.7 million for the third quarter of 2026, down from $115.5 million in the prior-year period, which included $53.1 million of one-time income tied to the sale of the Pelthos business. Excluding that divestiture-related income, core revenue grew 26% year over year. Royalty revenue, the company's central growth driver, rose 51% to $70.3 million, including $12.3 million from XOMA-acquired assets recognized in the roughly 11 weeks following the deal's close.

On a GAAP basis, Ligand posted a net loss of $28.5 million, or $1.43 per share, compared with net income of $117.3 million, or $5.68 per share, a year earlier. The swing primarily reflected $35 million of one-time XOMA transaction and integration costs and a $35.7 million non-cash mark-to-market loss on equity investments. Adjusted diluted EPS, which excludes such items, was $2.67, above the consensus estimate of approximately $2.30 but below the prior-year figure of $3.09, which benefited from one-time Zelsuvmi out-license income. General and administrative (G&A) expenses rose to $72.6 million from $28.4 million, largely due to acquisition-related costs and an expanded business development team.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking names like Ligand Pharmaceuticals, the tool offers a structured way to identify comparable opportunities across the biotech and royalty-financing landscape.

Market Reaction and Investor Sentiment

Investor sentiment into the report was mixed, as the headline year-over-year comparisons were distorted by last year's divestiture income. The clean adjusted EPS beat and the second guidance raise of the year reinforced confidence in the underlying royalty model, even though revenue guidance was only reaffirmed rather than increased. The market's interpretation focused on the quality of the royalty growth: legacy royalties grew 25% to $58.1 million, meaning the quarter did not depend solely on newly acquired assets. However, analysts noted that GAAP results remain noisy due to mark-to-market swings, and management acknowledged that some royalty figures, including Filspari, are based on consensus estimates because partner companies report on different schedules, leaving room for later true-ups.

Forward Outlook and Key Factors to Monitor

Ligand expects fourth-quarter revenue to strengthen, driven by a full quarter of XOMA royalties compared with the partial contribution in the third quarter. Many of the company's royalty agreements also include tiered rates that step up as product sales grow, with higher tiers typically reached later in the year.

For the full year, management reaffirmed royalty revenue guidance of $225 million to $250 million and total revenue of $270 million to $310 million, while raising adjusted diluted EPS guidance to $9.50 to $9.75. Investors will be watching whether the company delivers toward the upper end of the royalty range, given the wide implied fourth-quarter spread.

Beyond the current fiscal year, several catalysts could shape the story. Palvella's Qtorin rapamycin application received priority review with a U.S. Food and Drug Administration (FDA) decision date in February 2027, and management has pointed to up to seven pivotal clinical readouts through 2027. Capital deployment also remains active, including a $23 million royalty interest in Ryjunea and an up to $47 million financing with AvenCell Therapeutics. As always with royalty aggregators, the timing of partner product sales, milestones, and clinical outcomes remains a key variable in reported results.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations